Eyepoint Pharmac Stock Price, News & Analysis

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) has announced its participation in several upcoming conferences aimed at improving the lives of patients with serious eye disorders. The company will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 7:00 a.m. ET, and at the Baird 2022 Global Healthcare Conference on September 14, 2022, at 1:25 p.m. ET. Additionally, a Fireside Chat at the Guggenheim Nantucket Therapeutics Conference is scheduled for September 29, 2022, at 10:30 a.m. ET, followed by another on September 30, 2022, at 11:40 a.m. ET during the Benzinga Retail Conference.

EyePoint Pharmaceuticals reported a significant milestone with the first patient dosed in the Phase 2 DAVIO 2 clinical trial for wet AMD. The Phase 1 DAVIO results showcased a promising safety and efficacy profile for EYP-1901. Financially, the company achieved a 30% increase in net product revenue, totaling $11.3 million in Q2 2022. Operating expenses increased to $30.8 million, leading to a net loss of $19.4 million. The company is positioned to fund operations into 2024, buoyed by robust demand for products like YUTIQ® and DEXYCU®.

EyePoint Pharmaceuticals (NASDAQ: EYPT) recently announced its participation in two upcoming conferences. The BTIG Biotechnology Conference is scheduled for August 9, 2022, at 10:00 a.m. ET, featuring a panel discussion. Additionally, the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference will take place on August 17, 2022, with corporate presentations at 7:00 a.m. ET and 11:00 a.m. ET. Webcasts of both events will be available on the company's website, with replays accessible for 90 days.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the dosing of the first patient in the Phase 2 DAVIO 2 clinical trial for EYP-1901, aimed at treating wet age-related macular degeneration (wet AMD). The trial utilizes a 'Treat to Maintain' strategy, potentially reducing treatment frequency, as shown by Phase 1 results where 53% of patients didn't require additional treatment for six months. The Phase 2 trial will enroll around 150 patients, investigating the efficacy of EYP-1901 compared to aflibercept. Topline data is anticipated in the second half of 2023.

EyePoint Pharmaceuticals (NASDAQ: EYPT) will host a conference call on August 3, 2022, at 8:30 a.m. ET to discuss its Q2 2022 financial results and recent corporate developments. The company focuses on therapeutics for serious eye disorders, utilizing its Durasert® technology for sustained drug delivery. Its pipeline includes EYP-1901, targeting wet age-related macular degeneration. EyePoint's current marketed product is YUTIQ®, approved for chronic non-infectious uveitis. Interested parties can access the call via registration or by visiting the company website for a live audio webcast.

EyePoint Pharmaceuticals (NASDAQ: EYPT) recently shared promising 12-month safety and efficacy results from the Phase 1 DAVIO clinical trial for EYP-1901, aimed at treating wet AMD. The company expects to initiate dosing in a Phase 2 trial in Q3 2022 for both wet AMD and non-proliferative diabetic retinopathy. Q2 2022 net product revenue reached $11.3 million, a 30% increase year-over-year, with cash and investments totaling $171 million as of June 30, 2022. However, changes in reimbursement status for DEXYCU effective January 1, 2023, may pose financial challenges.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced the granting of stock options to nine new employees as inducement awards, in compliance with NASDAQ Listing Rule 5635(c)(4). A total of 18,000 options were issued on July 15, 2022, at an exercise price of $9.91, corresponding to the closing stock price on that date. The options will vest over four years, with 25% vesting on the first anniversary and the rest monthly thereafter. This strategic move aims to attract talented personnel to support the company's commitment to developing therapeutics for serious eye disorders.

EyePoint Pharmaceuticals announced positive 12-month results from the Phase 1 DAVIO clinical trial for EYP-1901, an anti-VEGF therapy aimed at treating wet AMD. The data revealed no ocular serious adverse events and stable visual acuity with a 35% rate of patients remaining supplement-free at 12 months. The company plans to initiate the Phase 2 trial (DAVIO2) in Q3 2022, targeting approximately 150 previously treated wet AMD patients. EYP-1901 shows promise for long-term maintenance therapy, with significant treatment burden reduction of 74% at 12 months.

EyePoint Pharmaceuticals (NASDAQ: EYPT) will host an Investor Day on July 18, 2022, from 8:00 a.m. to 11:00 a.m. ET. The event will feature commentary from the management team and guest speakers Carl Regillo, M.D., and Charles Wykoff, M.D., discussing the Durasert® drug delivery platform and the Phase 2 plans for EYP-1901, aimed at treating wet AMD. A live webcast will be available, with an archived replay accessible for 90 days post-event on the company's website.